Nanotechnology Now - Press Release: AMAG Pharmaceuticals, Inc. to Present at the Cowen and Company 28th Annual Health Care Conference

Home > Press > AMAG Pharmaceuticals, Inc. to Present at the Cowen and Company 28th Annual Health Care Conference

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO, will present an overview of the Company at the Cowen and Company 28th Annual Health Care Conference on Monday, March 17, 2008 at 11:30 a.m. The conference is being held March 17-20, 2008 in Boston, MA.

AMAG Pharmaceuticals, Inc. to Present at the Cowen and Company 28th Annual Health Care Conference

Cambridge, MA | Posted on March 5th, 2008

A live audio webcast of the presentation will be accessible through the Investors section of the Company's web site at www.amagpharma.com. Following the conference, the audio webcast will be archived on the AMAG Pharmaceuticals, Inc. website until March 31, 2008.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration in December 2007, which was accepted for filing in February 2008.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: